BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma.
Yulong HanQiuzhong PanZhixing GuoYufei DuYaojun ZhangYingying LiuJingjing ZhaoJinfeng XuJieying YangDijun OuyangYan TangQijing WangYongqiang LiJia HeMengjuan YangHao ChenChaopin YangXinyi YangJinqi YouYuanyuan ChenMinghao RenYao ZhuJian-Chuan XiaTong XiangPublished in: Clinical and translational medicine (2023)
HBV-induced BMP9 downregulation causes vascular abnormalities that inhibit intra-tumoural cytotoxic lymphocyte infiltration, providing a rationale for developing and combining immunotherapy with BMP9-based therapy to treat HBV-associated HCC.